<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04654650</url>
  </required_header>
  <id_info>
    <org_study_id>HHPHBiobank</org_study_id>
    <nct_id>NCT04654650</nct_id>
  </id_info>
  <brief_title>Prospective Registry and Biobank for Long-term Observational Studies in Adult Patients With Pulmonary Hypertension</brief_title>
  <official_title>Prospective Registry and Biobank for Long-term Observational Studies in Adult Patients With Pulmonary Hypertension</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Universitätsklinikum Hamburg-Eppendorf</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Universitätsklinikum Hamburg-Eppendorf</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Prospective registry and biobank for long-term observational studies in adult patients with&#xD;
      pulmonary hypertension&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In a prospective registry prevalent and incident patients diagnosed with group 1 to 5&#xD;
      pulmonary hypertension will be enrolled. In an integrated biobank body fluid samples will be&#xD;
      collected at enrollment and sequentially during treatment with targeted drugs for pulmonary&#xD;
      hypertension.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 26, 2021</start_date>
  <completion_date type="Anticipated">January 25, 2041</completion_date>
  <primary_completion_date type="Anticipated">January 25, 2041</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>20 Years</target_duration>
  <primary_outcome>
    <measure>Transplant-free survival</measure>
    <time_frame>Up to 20 years of follow-up after enrollment</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Risk score (averaging low, intermediate and high risk categories) as proposed by the 2015 European Society of Cardiology (ESC)/European Respiratory Society (ERS) guidelines for pulmonary hypertension</measure>
    <time_frame>Up to 20 years of follow-up after enrollment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Registry to Evaluate Early And Long-term PAH Disease Management (REVEAL) 2.0 risk score</measure>
    <time_frame>Up to 20 years of follow-up after enrollment</time_frame>
  </secondary_outcome>
  <enrollment type="Anticipated">5000</enrollment>
  <condition>Pulmonary Hypertension</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Patients diagnosed with pulmonary hypertension and patients referred to a pulmonary&#xD;
        hypertension center for suspected pulmonary hypertension.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Diagnosis of pulmonary hypertension group 1 to 5&#xD;
&#xD;
          -  Ability to give informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        - Withdrawal of informed consent&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Lars Harbaum, MD</last_name>
    <phone>+4940741018337</phone>
    <email>l.harbaum@uke.de</email>
  </overall_contact>
  <location>
    <facility>
      <name>Universitätsklinikum Hamburg-Eppendorf</name>
      <address>
        <city>Hamburg</city>
        <zip>20246</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lars Harbaum</last_name>
      <email>l.harbaum@uke.de</email>
    </contact>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>November 4, 2020</study_first_submitted>
  <study_first_submitted_qc>November 29, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 4, 2020</study_first_posted>
  <last_update_submitted>January 31, 2021</last_update_submitted>
  <last_update_submitted_qc>January 31, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 3, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension, Pulmonary</mesh_term>
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

